Article Contents ::
- 1 The Brand Name CARELOL Has Generic Salt :: Carvedilol
- 2 CARELOL Is From Company Cipla Priced :: Rs. 240
- 3 CARELOL have Carvedilol is comes under Sub class Anti Hypertensives of Main Class Cardiovascular System
- 4 Main Medicine Class:: Cardiovascular System Sub Medicine Class :: Anti Hypertensives
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name CARELOL Has Generic Salt :: Carvedilol
CARELOL Is From Company Cipla Priced :: Rs. 240
CARELOL have Carvedilol is comes under Sub class Anti Hypertensives of Main Class Cardiovascular System
Main Medicine Class:: Cardiovascular System Sub Medicine Class :: Anti Hypertensives
Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
Carvedilol | TAB | Rs. 240 | 100 |
Brand Name | Company / Manufacturers | Strength | Unit | Price / 100 |
CARELOL | Cipla | 3.125MG | 100 | Rs. 240 |
Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
From Cipla :: CARELOL | Carvedilol | Cardiovascular System | Anti Hypertensives |
Indications for Drugs ::
Hypertension, Congestive heart failure, Myocardial infarction, Left ventricular dysfunction, Angina pectoris
Drug Dose ::
Hypertension Adult: Initially, 12.5 mg once daily increased to 25 mg once daily after 2 days. Alternatively, initial dose of 6.25 mg bid increased to 12.5 mg bid after 1-2 wk, increased further if necessary to 50 mg once daily or in divided doses. Elderly: 12.5 mg once daily. Angina pectoris Adult: Initially, 12.5 mg bid increased to 25 mg bid after 2 days. Heart failure Adult: Initially, 3.125 mg bid, doubled to 6.25 mg bid after 2 wk if tolerated, then gradually increased to the max dose the patient can tolerate at intervals of not <2>85 kg: 50 mg bid; <85 kg: 25 mg bid. Left ventricular dysfunction post myocardial infarction Adult: Initially: 6.25 mg bid, if tolerated, after 3-10 days, increase to 12.5 mg bid and then to a target dose of 25 mg bid.
Contraindication ::
Hypersensitivity; severe chronic heart failure, bronchial asthma or related bronchospastic conditions; severe hepatic impairment. Patients with NYHA class IV cardiac failure, 2nd or 3rd ° AV block, sick sinus syndrome (unless a permanent pacemaker is in place), cardiogenic shock or severe bradycardia. Lactation.
Drug Precautions ::
Avoid abrupt withdrawal as it may precipitate thyroid storm or exacerbate hyperthyroidism. Liver injury; vascular disease, renal failures, suspected phaeochromocytoma and prinzmetal’s variable angina; worsening cardiac failure or fluid retention during increase in dosage of carvedilol; diabetic patients. Pregnancy.
Drug Side Effects ::
Bradycardia, AV block, angina pectoris, hypervolaemia, leucopenia, hypotension, peripheral oedema, allergy, malaise, fluid overload, melena, periodontitis, hyperuricaemia, hyponatraemia, increased alkaline phosphatase, glycosuria, prothrombin time, SGPT and SGOT levels, purpura, somnolence, impotence, albuminuria, hypokinesia, nervousness, sleep disorder, skin reaction, tinnitus, dry mouth, anaemia, sweating, fatigue, arthralgia, aggravation, dizziness. Diarrhoea, nausea, vomiting, insomnia, hypercholesterolaemia, weight gain, abnormal vision, rhinitis, pharyngitis and hypertriglyceridaemia.
Pregnancy category ::
4
Drug Mode of Action ::
Carvedilol is a nonselective beta-adrenoreceptor and alpha-adrenergic blocking activity. It exerts antihypertensive effect partly by reducing total peripheral resistance and vasodilation.
Drug Interactions ::
Decreased serum levels w/ rifampicin. Combination w/ Ca channel blockers (e.g. verapamil and diltiazem) can lead to bradycardia and myocardial depression. Potentiates insulin-induced hypoglycaemic action. May increase hypoglycaemic effects of antidiabetic agents. Increased risk of bradycardia w/ digoxin. Increased risk of hypotension and bradycardia w/ reserpine, MAOIs, clonidine. May increase ciclosporin concentrations. Concurrent use w/ ether, cyclopropane, trichloroethylene may increase the risk of hypotension and heart failure.